|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:acquisition
|
acquired by Lundbeck
|
|
gptkbp:business_model
|
gptkb:Company
|
|
gptkbp:can_lead_to
|
Eptinezumab (brand name Vyepti)
|
|
gptkbp:ceo
|
gptkb:Mark_J._Rothera
|
|
gptkbp:clinical_trial
|
conducted in various locations
focused on neurological disorders
Phase 3 trials for Eptinezumab
conducted for migraine prevention
|
|
gptkbp:collaborations
|
with academic institutions
|
|
gptkbp:committee
|
comprised of industry experts
|
|
gptkbp:community_engagement
|
involved in patient advocacy
|
|
gptkbp:financial_performance
|
reported revenue growth
|
|
gptkbp:focus
|
development of therapies for migraine
|
|
gptkbp:founded
|
gptkb:2004
|
|
gptkbp:founder
|
gptkb:Randall_C._Schatzman
|
|
gptkbp:headquarters
|
gptkb:Bothell,_Washington
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Alder Biopharmaceuticals
|
|
gptkbp:invention
|
multiple patents for drug formulations
|
|
gptkbp:investment
|
various venture capital firms
secured funding from investors
|
|
gptkbp:ipo
|
gptkb:2017
|
|
gptkbp:language_of_instruction
|
multiple drug candidates in development
|
|
gptkbp:leadership
|
experienced management team
|
|
gptkbp:market
|
gptkb:United_States
|
|
gptkbp:mission
|
to improve the lives of patients with migraine
|
|
gptkbp:partnership
|
collaborated with other pharmaceutical companies
|
|
gptkbp:partnerships
|
formed strategic alliances
|
|
gptkbp:products
|
gptkb:Eptinezumab
|
|
gptkbp:regulatory_compliance
|
received FDA approval for Eptinezumab
|
|
gptkbp:research_areas
|
neurology
|
|
gptkbp:research_focus
|
CGRP inhibitors
|
|
gptkbp:symbol
|
ALDR
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:type
|
gptkb:Company
|
|
gptkbp:website
|
www.alderbio.com
|
|
gptkbp:bfsParent
|
gptkb:ALX-0704
|
|
gptkbp:bfsLayer
|
5
|